David Fruman is a Professor of Molecular Biology & Biochemistry at UC Irvine. He obtained his B.S. in Biological Sciences from Stanford University and his Ph.D. in Immunology from Harvard University. After completing postdoctoral work in the laboratories of Lewis Cantley and Owen Witte, he joined the faculty at UCI in 2000. His research interest is signal transduction in lymphocytes, with an emphasis on targeted therapies for blood cancer and immune diseases. He has devoted much of his career to studying the PI3K/mTOR signaling pathway. Recently his lab established a new research focus on repurposing statin drugs to enhance efficacy of BH3 mimetic drugs (e.g. venetoclax) in blood cancer. He previously served as Associate Director of the UCI Institute for Immunology and is currently the Director of the UCI Cancer Research Institute. He is also Associate Director for Basic Science of the NCI-designated Chao Family Comprehensive Cancer Center. In 2016 he was elected as a AAAS Fellow.